136 related articles for article (PubMed ID: 28498400)
1. TRIM28 knockdown increases sensitivity to etoposide by upregulating E2F1 in non-small cell lung cancer.
Liu L; Xiao L; Liang X; Chen L; Cheng L; Zhang L; Wu X; Xu Q; Ma C
Oncol Rep; 2017 Jun; 37(6):3597-3605. PubMed ID: 28498400
[TBL] [Abstract][Full Text] [Related]
2. Downregulation of TRIM28 inhibits growth and increases apoptosis of nude mice with non‑small cell lung cancer xenografts.
Liu L; Zhang L; Wang J; Zhao X; Xu Q; Lu Y; Zuo Y; Chen L; Du J; Lian Y; Zhang Q
Mol Med Rep; 2018 Jan; 17(1):835-842. PubMed ID: 29115614
[TBL] [Abstract][Full Text] [Related]
3. TRIM28 promotes cervical cancer growth through the mTOR signaling pathway.
Li F; Wang Z; Lu G
Oncol Rep; 2018 Apr; 39(4):1860-1866. PubMed ID: 29393469
[TBL] [Abstract][Full Text] [Related]
4. E2F1 downregulation by arsenic trioxide in lung adenocarcinoma.
Lam SK; Li YY; Zheng CY; Leung LL; Ho JC
Int J Oncol; 2014 Nov; 45(5):2033-43. PubMed ID: 25174355
[TBL] [Abstract][Full Text] [Related]
5. TRIM28, a new molecular marker predicting metastasis and survival in early-stage non-small cell lung cancer.
Liu L; Zhao E; Li C; Huang L; Xiao L; Cheng L; Huang X; Song Y; Xu D
Cancer Epidemiol; 2013 Feb; 37(1):71-8. PubMed ID: 22959342
[TBL] [Abstract][Full Text] [Related]
6. ANKRD22 promotes progression of non-small cell lung cancer through transcriptional up-regulation of E2F1.
Yin J; Fu W; Dai L; Jiang Z; Liao H; Chen W; Pan L; Zhao J
Sci Rep; 2017 Jun; 7(1):4430. PubMed ID: 28667340
[TBL] [Abstract][Full Text] [Related]
7. Small interfering RNA-mediated suppression of serum response factor, E2-promotor binding factor and survivin in non-small cell lung cancer cell lines by non-viral transfection.
Walker T; Nolte A; Steger V; Makowiecki C; Mustafi M; Friedel G; Schlensak C; Wendel HP
Eur J Cardiothorac Surg; 2013 Mar; 43(3):628-33; discussion 633-4. PubMed ID: 23152437
[TBL] [Abstract][Full Text] [Related]
8. A new strategy in the treatment of chemoresistant lung adenocarcinoma via specific siRNA transfection of SRF, E2F1, Survivin, HIF and STAT3.
Stoleriu MG; Steger V; Mustafi M; Michaelis M; Cinatl J; Schneider W; Nolte A; Kurz J; Wendel HP; Schlensak C; Walker T
Eur J Cardiothorac Surg; 2014 Nov; 46(5):877-86. PubMed ID: 24627437
[TBL] [Abstract][Full Text] [Related]
9. Etoposide enhances antitumor efficacy of MDR1-driven oncolytic adenovirus through autoupregulation of the MDR1 promoter activity.
Su BH; Shieh GS; Tseng YL; Shiau AL; Wu CL
Oncotarget; 2015 Nov; 6(35):38308-26. PubMed ID: 26515462
[TBL] [Abstract][Full Text] [Related]
10. Co-delivery of VEGF siRNA and Etoposide for Enhanced Anti-angiogenesis and Anti-proliferation Effect
Li F; Wang Y; Chen WL; Wang DD; Zhou YJ; You BG; Liu Y; Qu CX; Yang SD; Chen MT; Zhang XN
Theranostics; 2019; 9(20):5886-5898. PubMed ID: 31534526
[TBL] [Abstract][Full Text] [Related]
11. Elevated expression of BIRC6 protein in non-small-cell lung cancers is associated with cancer recurrence and chemoresistance.
Dong X; Lin D; Low C; Vucic EA; English JC; Yee J; Murray N; Lam WL; Ling V; Lam S; Gout PW; Wang Y
J Thorac Oncol; 2013 Feb; 8(2):161-70. PubMed ID: 23287853
[TBL] [Abstract][Full Text] [Related]
12. Lentivirus-delivered ZEB-1 small interfering RNA inhibits lung adenocarcinoma cell growth in vitro and in vivo.
Liu Y; Yan X; Liu N; Zhou J; Liu J; Pang H; Cao J; Liu Y; Wang Y; Liu L; Zhang H
J Cancer Res Clin Oncol; 2012 Aug; 138(8):1329-38. PubMed ID: 22481253
[TBL] [Abstract][Full Text] [Related]
13. Resveratrol Enhances Etoposide-Induced Cytotoxicity through Down-Regulating ERK1/2 and AKT-Mediated X-ray Repair Cross-Complement Group 1 (XRCC1) Protein Expression in Human Non-Small-Cell Lung Cancer Cells.
Ko JC; Syu JJ; Chen JC; Wang TJ; Chang PY; Chen CY; Jian YT; Jian YJ; Lin YW
Basic Clin Pharmacol Toxicol; 2015 Dec; 117(6):383-91. PubMed ID: 26046675
[TBL] [Abstract][Full Text] [Related]
14. PLAUR Confers Resistance to Gefitinib Through EGFR/P-AKT/Survivin Signaling Pathway.
Zhou J; Kwak KJ; Wu Z; Yang D; Li J; Chang M; Song Y; Zeng H; Lee LJ; Hu J; Bai C
Cell Physiol Biochem; 2018; 47(5):1909-1924. PubMed ID: 29961070
[TBL] [Abstract][Full Text] [Related]
15. Interferon regulatory factor 4 (IRF4) is overexpressed in human non‑small cell lung cancer (NSCLC) and activates the Notch signaling pathway.
Qian Y; Du Z; Xing Y; Zhou T; Chen T; Shi M
Mol Med Rep; 2017 Nov; 16(5):6034-6040. PubMed ID: 28849037
[TBL] [Abstract][Full Text] [Related]
16. Silencing survivin expression inhibits the tumor growth of non-small-cell lung cancer cells in vitro and in vivo.
Zhang K; Li Y; Liu W; Gao X; Zhang K
Mol Med Rep; 2015 Jan; 11(1):639-44. PubMed ID: 25333812
[TBL] [Abstract][Full Text] [Related]
17. Response of non-small cell lung cancer cells to the inhibitors of phosphatidylinositol 3-kinase/Akt- and MAPK kinase 4/c-Jun NH2-terminal kinase pathways: an effective therapeutic strategy for lung cancer.
Lee HY; Oh SH; Suh YA; Baek JH; Papadimitrakopoulou V; Huang S; Hong WK
Clin Cancer Res; 2005 Aug; 11(16):6065-74. PubMed ID: 16115952
[TBL] [Abstract][Full Text] [Related]
18. Identification of KvLQT1 K+ channels as new regulators of non-small cell lung cancer cell proliferation and migration.
Girault A; Privé A; Trinh NT; Bardou O; Ferraro P; Joubert P; Bertrand R; Brochiero E
Int J Oncol; 2014 Mar; 44(3):838-48. PubMed ID: 24366043
[TBL] [Abstract][Full Text] [Related]
19. Physalin A exerts anti-tumor activity in non-small cell lung cancer cell lines by suppressing JAK/STAT3 signaling.
Zhu F; Dai C; Fu Y; Loo JF; Xia D; Gao SP; Ma Z; Chen Z
Oncotarget; 2016 Feb; 7(8):9462-76. PubMed ID: 26843613
[TBL] [Abstract][Full Text] [Related]
20. lncRNA-HIT promotes cell proliferation of non-small cell lung cancer by association with E2F1.
Yu L; Fang F; Lu S; Li X; Yang Y; Wang Z
Cancer Gene Ther; 2017 May; 24(5):221-226. PubMed ID: 28429752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
